MCID: ESS001
MIFTS: 60

Essential Tremor malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Essential Tremor

About this section

Aliases & Descriptions for Essential Tremor:

Name: Essential Tremor 49 10 45 23 46 47 12 36 65
Benign Essential Tremor 10 45 23
Tremor, Hereditary Essential, 1 45 65
Tremor, Hereditary Essential 1 67 24
Hereditary Essential Tremor 45 23
Familial Tremor 23 65
Etm1 45 67
Essential Tremor, Susceptibility to 11
 
Tremor Hereditary Essential, 1 45
Hereditary Essential Tremor 1 22
Tremor Familial Essential, 1 45
Essential Hereditary Tremor 10
Familial Essential Tremor 45
Presenile Tremor Syndrome 45
Shaky Hand Syndrome 10
Fet1 45

Characteristics:

HPO:

61
essential tremor:
Onset and clinical course: progressive
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 190300
Disease Ontology10 DOID:4990
ICD1027 G25.0
SNOMED-CT59 192839001, 632009
MeSH36 D020329
MedGen34 C1860861
UMLS65 C0270736, C0393615, C1860861

Summaries for Essential Tremor

About this section
NIH Rare Diseases:45 Essential tremor is the most common movement disorder.  it is characterized by involuntary and rhythmic shaking (tremor), especially in the hands, without any other signs or symptoms. it is distinguished from tremor that results from other disorders or known causes, such as tremors seen with parkinson disease or head trauma. most cases of essential tremor are hereditary. there are five forms of essential tremor that are based on different genetic causes. several genes as well as lifestyle and environmental factors likely play a role in a person's risk of developing this complex condition. in mild cases, treatment may not be necessary. in cases where symptoms interfere with daily living, medications may help to relieve symptoms.      last updated: 9/12/2014

MalaCards based summary: Essential Tremor, also known as benign essential tremor, is related to sensorineural hearing loss-early graying-essential tremor syndrome and tremor, and has symptoms including hand tremor, postural tremor and dysarthria. An important gene associated with Essential Tremor is DRD3 (Dopamine Receptor D3), and among its related pathways are Alpha-synuclein signaling and Parkinsons Disease Pathway. The drugs propranolol and propranolol hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and lung, and related mouse phenotype nervous system.

Disease Ontology:10 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms.

Genetics Home Reference:23 Essential tremor is a movement disorder that causes involuntary, rhythmic shaking (tremor), especially in the hands. It is distinguished from tremor that results from other disorders or known causes, such as Parkinson disease or head trauma. Essential tremor usually occurs alone, without other neurological signs or symptoms. However, some experts think that essential tremor can include additional features, such as mild balance problems.

OMIM:49 Essential tremor may be the most common human movement disorder. The main feature of essential tremor is postural... (190300) more...

NINDS:46 Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. Essential tremor (previously called benign essential tremor) is the most common form of abnormal tremor. (In some people, tremor is a symptom of a neurological disorder or appears as a side effect of certain drugs.)

UniProtKB/Swiss-Prot:67 Tremor, hereditary essential 1: A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles also may be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant.

Wikipedia:68 Essential tremor (ET, also referred to as benign tremor, familial tremor, or idiopathic tremor) is the... more...

Related Diseases for Essential Tremor

About this section

Diseases in the Tremor family:

Tremor, Hereditary Essential, 2 essential tremor
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4

Diseases related to Essential Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 66)
idRelated DiseaseScoreTop Affiliating Genes
1sensorineural hearing loss-early graying-essential tremor syndrome12.1
2tremor11.1
3tremor, hereditary essential, 411.1
4neuhauser daly magnelli syndrome11.1
5schizophrenia11.1
6angelman syndrome due to a point mutation10.5LRRK2, SNCA
7deep brain stimulation for parkinson's disease10.4
8parkinson disease 6, early onset10.4LRRK2, PARK2
9kleptomania10.4DRD3, SLC6A3
10tuberculous epididymitis10.4HS1BP3, PARK2
11epilepsy, progressive myoclonic 1b10.4LRRK2, PARK2
12dystonia10.3
13testicular leydig cell tumor10.3SLC6A3, SNCA
14iron-refractory iron deficiency anemia10.2PARK2, SNCA
15esophagus carcinoma in situ10.2LRRK2, SLC6A3, SNCA
16coenzyme q10 deficiency, primary, 110.2PARK2, SNCA
17dubowitz syndrome10.2SLC6A3, SNCA
18snrnp200-related retinitis pigmentosa10.2LRRK2, PARK2, SNCA
19cervical dystonia10.2
20cervicitis10.2
21pde6d-related joubert syndrome10.1LRRK2, SNCA
22mast syndrome10.1LRRK2, PARK2, SNCA
23hypotrichosis 710.1PARK2, SNCA
24colon kaposi sarcoma10.1LRRK2, PARK2, SNCA
25restless legs syndrome10.0
26neuronitis10.0
27ataxia10.0
28multiple system atrophy10.0
29dementia10.0
30nephronophthisis-like nephropathy 19.9
31pick disease9.9FUS, LRRK2, PARK2, SNCA
32sarcoma9.9
33cerebritis9.9
34supranuclear palsy, progressive atypical9.9LRRK2, PARK2, SLC6A3, SNCA
35adrenal cortical adenoma9.9LRRK2, PARK2, SLC6A3, SNCA
36polycystic kidney disease 29.8LRRK2, PARK2, SLC6A3, SNCA
37parkinson disease 19.8LRRK2, PARK2, SLC6A3, SNCA
38candidiasis9.8DRD3, FMR1, SLC6A3, SNCA
39atopic dermatitis9.8LRRK2, PARK2, SLC6A3, SNCA
40cerebellar ataxia9.7
41alzheimer disease9.7
42obsessive-compulsive disorder9.7
43hereditary ataxia9.7
44hydrocephalus9.7
45apraxia9.7
46hypothyroidism9.7
47normal pressure hydrocephalus9.7
48klinefelter's syndrome9.7
49lateral sclerosis9.7
50agnosia9.7

Graphical network of the top 20 diseases related to Essential Tremor:



Diseases related to essential tremor

Symptoms for Essential Tremor

About this section

Symptoms by clinical synopsis from OMIM:

190300

Clinical features from OMIM:

190300

HPO human phenotypes related to Essential Tremor:

id Description Frequency HPO Source Accession
1 hand tremor HP:0002378
2 postural tremor HP:0002174
3 dysarthria HP:0001260

UMLS symptoms related to Essential Tremor:


tremor nec in icd9cm_2014, hyperexplexia, tremor, essential and other specified forms of tremor, orthostatic tremor, physiological tremor, head titubation, tremor, neonatal, static tremor, action tremor, asterixis, senile tremor, myoclonus

Drugs & Therapeutics for Essential Tremor

About this section

Drugs for Essential Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 154)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Pregabalinapproved, illicit, investigationalPhase 4340148553-50-85486971
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3-Isobutyl gaba
3-isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
CID5486971
 
D02716
DB00230
FT-0080911
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
2
Memantineapproved, investigationalPhase 417219982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
3
Propranololapproved, investigationalPhase 4202525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Hemangeol
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal LA
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
 
Innopran XL
Innopran Xl
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
4
DopamineapprovedPhase 4, Phase 3308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
5
AcetylcholineexperimentalPhase 4, Phase 3, Phase 268951-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
Miochol E
O-Acetylcholine
acetylcholine chloride
6Anti-Arrhythmia AgentsPhase 4, Phase 12371
7Adrenergic beta-AntagonistsPhase 4979
8Adrenergic AntagonistsPhase 41253
9Adrenergic AgentsPhase 4, Phase 3, Phase 2, Phase 14204
10Antihypertensive AgentsPhase 4, Phase 13618
11Botulinum ToxinsPhase 4, Phase 3, Phase 2616
12Pharmaceutical SolutionsPhase 4, Phase 2, Phase 17004
13Excitatory Amino Acid AntagonistsPhase 41095
14Vasodilator AgentsPhase 42926
15Antiparkinson AgentsPhase 4, Phase 31312
16Cholinergic AgentsPhase 4, Phase 3, Phase 2, Phase 13243
17Psychotropic DrugsPhase 4, Phase 15501
18AnalgesicsPhase 4, Phase 2, Phase 39358
19Anti-Anxiety AgentsPhase 4, Phase 11529
20Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 114795
21Dopamine AgentsPhase 4, Phase 33084
22Excitatory Amino AcidsPhase 41109
23AnticonvulsantsPhase 4, Phase 3, Phase 2, Phase 12249
24calcium channel blockersPhase 41743
25Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 118510
26Tranquilizing AgentsPhase 4, Phase 13597
27Central Nervous System DepressantsPhase 4, Phase 2, Phase 3, Phase 110016
28Calcium, DietaryPhase 4, Phase 24678
29
IodinePhase 44947553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
30cadexomer iodinePhase 4456
31CalamusNutraceuticalPhase 4344
32
PhenylephrineapprovedPhase 3, Phase 140959-42-76041
Synonyms:
(-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
(R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine
(R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol
1416-03-1
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
59-42-7
61-76-7 (hydrochloride)
AC1L1LO9
AC1Q40UF
AI3-02402
AK-Dilate
AK-Nefrin
Adrianol
Ah-Chew
Ak-Dilate
Ak-Nefrin
Ak-dilate
Ak-nefrin
Alcon Efrin
Alcon efrin
Alconefrin Nasal Drops 12
Alconefrin Nasal Drops 25
Alconefrin Nasal Drops 50
Alconefrin Nasal Spray 25
BIDD:GT0157
BSPBio_002420
Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)- (9CI)
Biomydrin
C07441
CCRIS 8464
CHEBI:8093
CHEMBL1215
CID6041
Cyclomydril
D08365
DB00388
Dilatair
Dimetane
Dionephrine
DivK1c_000597
Doktors
Duration
EINECS 200-424-8
EINECS 215-810-1
Fenilefrina
Fenilefrina [INN-Spanish]
HSDB 3383
Help I Have A Stuffy Nose
I-Phrine
IDI1_000597
Isophrim
Isophrin
Isopto Frin
KBio1_000597
KBio2_001581
KBio2_004149
KBio2_006717
KBio3_001640
KBioGR_001313
KBioSS_001581
L-Phenylephedrine
L-Phenylephrine
LS-43027
Lopac-P-6126
Lopac0_000920
M-Methylaminoethanolphenol
M-Oxedrine
M-Sympathol
M-Sympatol
M-Synephrine
Mesaton
 
Mesatone
Mesatonum
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasympatol
Metasynephrine
Metsatonum
Mezaton
Minims Phenylephrine
MolPort-001-792-191
Mydfrin
NCGC00015825-01
NCGC00015825-02
NCGC00024257-03
NCGC00024257-05
NCGC00024257-06
NINDS_000597
Neo-Synephrine
Neo-Synephrine Nasal Drops
Neo-Synephrine Nasal Jelly
Neo-Synephrine Nasal Spray
Neo-Synephrine Pediatric Nasal Drops
Neofrin
Neophryn
Neosynephrine
North Sinus Decongestant
Nostril
Nostril Spray Pump
Nostril Spray Pump Mild
Ocu-Phrin Sterile Eye Drops
Ocu-Phrin Sterile Ophthalmic Solution
Ocugestrin
P0395
PDSP1_001108
PDSP2_001092
Phenoptic
Phenylephrine
Phenylephrine (INN)
Phenylephrine Hydrochloride
Phenylephrine Minims
Phenylephrine Minims (TN)
Phenylephrine [INN:BAN]
Phenylephrine hydrochloride
Phenylephrinum
Phenylephrinum [INN-Latin]
Prefrin
Prefrin Liquifilm
Pyracort D
R(-)-Mezaton
R(-)-Phenylephrine
Relief Eye Drops for Red Eyes
Rhinall
SPBio_001280
Spectrum2_001280
Spectrum3_000770
Spectrum4_000967
Spectrum5_001411
Spectrum_001101
Spersaphrine
Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol
UNII-1WS297W6MV
Vicks Sinex
Visadron
l-(3-Hydroxyphenyl)-N-methylethanolamine
l-1-(m-Hydroxyphenyl)-2-methylaminoethanol
l-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene
l-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol
m-Methylaminoethanolphenol
m-Oxedrine
m-Sympathol
m-Sympatol
m-Synephrine
phenylephrine
33
OxymetazolineapprovedPhase 3, Phase 14091491-59-44636
Synonyms:
1491-59-4
2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
3-[(4,5-dihydro-1H-Imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
AC-6370
AC1L1IM1
Afrin Cherry 12 Hour Nasal Spray
Afrin Extra Moisturizing 12 Hour Nasal Spray
Afrin Original 12 Hour Nasal Spray
Afrin Original 12 Hour Nose Drops
Afrin Original 12 Hour Pump Mist
Afrin Sinus 12 Hour Nasal Spray
BPBio1_000295
BPBio1_000419
BRD-K16195444-001-01-7
BRN 0886303
BSPBio_000267
BSPBio_002145
Biomol-NT_000161
C07363
CAS-151615
CHEBI:142520
CHEMBL762
CID4636
D010109
D08322
DB00935
DivK1c_000567
Dristan Long Lasting Mentholated Nasal Spray
Dristan Long Lasting Nasal Mist
Drixoral Nasal Solution
Duramist Plus Up To 12 Hour Nasal Decongestant Spray
EINECS 216-079-1
FT-0082560
Genasal Nasal Spray Up to 12 Hour Relief
H 990
HMS2089G03
HSDB 3143
Hazol
IDI1_000567
Iliadin
KBio1_000567
KBio2_001531
KBio2_004099
KBio2_006667
KBio3_001645
KBioGR_000908
KBioSS_001531
L000459
LS-104146
Lopac-O-2378
Lopac0_000903
 
MolPort-002-538-313
Mucinex Full Force
Mucinex Moisture Smart
NCGC00015766-01
NCGC00015766-02
NCGC00015766-03
NCGC00015766-10
NCGC00022345-02
NCGC00022345-04
NCGC00022345-05
NCGC00022345-06
NINDS_000567
Nafrine
Nasal Relief 12 Hour Nasal Spray
Navasin
Navisin
Neo-Synephrine 12 Hour Spray
Nezeril
Nostrilla 12 Hour Nasal Decongestant
Operil (TN)
Oximetazolina
Oximetazolina [INN-Spanish]
Oximetazolinum
Oxylazine
Oxymetazolina
Oxymetazoline (INN)
Oxymetazoline Hydrochloride
Oxymetazoline [INN:BAN]
Oxymetazoline hydrochloride
Oxymetazoline hydrochloride crystalline
Oxymetazolinum
Oxymetazolinum [INN-Latin]
Oxymethazoline
Oxymetozoline
Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- (9CI)
Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- (7CI,8CI)
Prestwick0_000224
Prestwick1_000224
Prestwick2_000224
Prestwick3_000224
Rhinofrenol
Rhinolitan
SPBio_001095
SPBio_002188
Sinerol
Spectrum2_000998
Spectrum3_000533
Spectrum4_000464
Spectrum5_001114
Spectrum_001051
Tocris-1142
UNII-8VLN5B44ZY
Vicks Sinex 12 Hour Nasal Spray
Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief
Visine L.R
Visine L.R.
nchembio705-11
oxymeta zoline
oxymetazoline
oxymetazoline hydrochloride crystalline
34
TopiramateapprovedPhase 324097240-79-45284627
Synonyms:
-D-fructopyranose deriv.
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
CPD000466325
Cilag brand of topiramate
D00537
DB00273
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
MLS000759431
MLS001424070
McN 4853
McN-4853
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
Ortho brand of topiramate
 
Qudexy XR
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
STOCK1N-71037
Spectrum2_001128
T0575_SIGMA
TL8006021
TOR
TPM
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
Trokendi Xr
UNII-0H73WJJ391
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
topiramate
topiramate tablet
topiramatum [Latin]
35
Pramipexoleapproved, investigationalPhase 3137104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
KBio2_007476
 
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole Dihydrochloride Extended-Release
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
36ParasympatholyticsPhase 3, Phase 2, Phase 1902
37Respiratory System AgentsPhase 3, Phase 2, Phase 13931
38Tiotropium BromidePhase 3, Phase 2, Phase 1311
39Hypnotics and SedativesPhase 2, Phase 3, Phase 12032
40AntioxidantsPhase 3, Phase 2, Phase 12442
41
Salmeterol xinafoatePhase 3, Phase 2, Phase 132694749-08-356801
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
 
GR-33343 G
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
SMR000875207
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent Inhaler and Disks
Serevent diskus
UNII-6EW8Q962A5
Ultrabeta
salmeterol xinafoate
42Bronchodilator AgentsPhase 3, Phase 2, Phase 12377
43Protective AgentsPhase 3, Phase 2, Phase 15651
44Neuroprotective AgentsPhase 3, Phase 1, Phase 21376
45Anti-Obesity AgentsPhase 3354
46Adrenergic AgonistsPhase 3, Phase 2, Phase 12331
47Adrenergic beta-2 Receptor AgonistsPhase 3, Phase 2, Phase 1741
48Anti-Asthmatic AgentsPhase 3, Phase 2, Phase 12796
49Cholinergic AntagonistsPhase 3, Phase 2, Phase 11423
50Adrenergic beta-AgonistsPhase 3, Phase 2, Phase 11266

Interventional clinical trials:

(show top 50)    (show all 186)
idNameStatusNCT IDPhase
1A Pilot Clinical Trial Of Memantine for Essential TremorCompletedNCT00439699Phase 4
2Pregabalin (Lyrica) for the Treatment of Essential TremorCompletedNCT00584376Phase 4
3Pregabalin in the Treatment of Essential TremorCompletedNCT00646451Phase 4
4Propranolol and Botulinum Toxin for Essential Vocal TremorCompletedNCT02111369Phase 4
5RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)CompletedNCT00998660Phase 4
6A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar SymptomsCompletedNCT00382967Phase 4
7DaTSCAN Imaging in Aging and Neurodegenerative DiseaseEnrolling by invitationNCT01453127Phase 4
8Validation of DaTscan for Detection of Parkinson Disease Related DisordersEnrolling by invitationNCT02138682Phase 4
9Atlas Predicted DBS Settings in Essential TremorNot yet recruitingNCT02678429Phase 4
10Novel Therapies for Essential TremorCompletedNCT00018564Phase 3
11A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.CompletedNCT00236496Phase 3
12Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor PatientsCompletedNCT00468078Phase 3
13Tiotropium and Salmeterol PK Study in COPD PatientsCompletedNCT00673478Phase 3
14Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBSRecruitingNCT02549859Phase 2, Phase 3
15Efficacy of Pramipexole Extended Release in the Treatment of Essential TremorNot yet recruitingNCT01441284Phase 3
16Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential TremorNot yet recruitingNCT02555982Phase 3
17Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity TremorNot yet recruitingNCT00724906Phase 3
18Pre-lemniscal Radiation Deep Brain Stimulation for ETTerminatedNCT00634478Phase 2, Phase 3
19Dexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationWithdrawnNCT00608231Phase 2, Phase 3
20A Safety/Efficacy Trial of Zonisamide for Essential TremorCompletedNCT00223743Phase 2
21A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential TremorCompletedNCT00524056Phase 2
22Octanol to Treat Essential TremorCompletedNCT00080366Phase 2
23Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential TremorCompletedNCT00848172Phase 1, Phase 2
24Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential TremorCompletedNCT00102596Phase 2
25Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential TremorCompletedNCT00598078Phase 2
26A Pilot Efficacy and Safety Study of ST101 in Essential TremorCompletedNCT01332695Phase 2
27Evaluate SAGE-547 in Patients With Essential TremorCompletedNCT02277106Phase 2
28Efficacy of Levetiracetam in Essential TremorCompletedNCT00620165Phase 1, Phase 2
29Effect of Alcohol on TremorsCompletedNCT00001925Phase 2
30Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242266Phase 2
31Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242227Phase 2
32Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238106Phase 2
33An Efficacy/Safety Study of Perampanel for Reducing Essential TremorRecruitingNCT02668146Phase 2
34Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic AssessmentRecruitingNCT02551848Phase 2
35Botulinum Toxin A to Treat Arm TremorRecruitingNCT02207946Phase 2
36Effects of Octanoic Acid for Treatment of Essential Voice TremorRecruitingNCT01864525Phase 1, Phase 2
37Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and TremorRecruitingNCT01945567Phase 2
38Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot StudyRecruitingNCT02585583Phase 2
39Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson DiseaseEnrolling by invitationNCT02427646Phase 2
40A Study of T2000 in Essential TremorTerminatedNCT00321087Phase 2
41T2000 in Essential Tremor - Open Label ContinuationTerminatedNCT00655278Phase 2
421-Octanol to Treat Essential TremorCompletedNCT00016679Phase 1
43Octanoic Acid for Essential TremorCompletedNCT01468948Phase 1
441-Octanol to Treat Essential TremorCompletedNCT00001986Phase 1
45ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential TremorCompletedNCT02037217Phase 1
46ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential TremorCompletedNCT01304758Phase 1
47Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement DisordersCompletedNCT01698450Phase 1
48Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating FemalesCompletedNCT02211911Phase 1
49Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian OriginCompletedNCT02170909Phase 1
50Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis PatientsCompletedNCT02172534Phase 1

Search NIH Clinical Center for Essential Tremor

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: essential tremor

Genetic Tests for Essential Tremor

About this section

Genetic tests related to Essential Tremor:

id Genetic test Affiliating Genes
1 Hereditary Essential Tremor 122 DRD3

Anatomical Context for Essential Tremor

About this section

MalaCards organs/tissues related to Essential Tremor:

33
Brain, T cells, Lung, Liver, Breast, Prostate, Heart

Animal Models for Essential Tremor or affiliated genes

About this section

MGI Mouse Phenotypes related to Essential Tremor:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036317.6DRD3, FMR1, HTRA2, LINGO1, LRRK2, PARK2

Publications for Essential Tremor

About this section

Articles related to Essential Tremor:

(show top 50)    (show all 633)
idTitleAuthorsYear
1
Time reproduction deficits in essential tremor patients. (27091412)
2016
2
Cerebellar dysfunction in essential tremor. (27062434)
2016
3
Essential tremor seems to be a risk factor for Parkinson's disease. (26972525)
2016
4
Head tremor in essential tremor: "Yes-yes", "no-no", or "round and round"? (26563987)
2015
5
Genetic analysis of FMR1 repeat expansion in essential tremor. (25796179)
2015
6
Mapping Purkinje Cell Placement Along the Purkinje Cell Layer: an Analysis of Postmortem Tissue from Essential Tremor Patients vs. Controls. (26563297)
2015
7
Are Patients with Limb and Head Tremor a Clinically Distinct Subtype of Essential Tremor? (25857448)
2015
8
Non-steroidal anti-inflammatory drug use and essential tremor. (25376662)
2014
9
Re-thinking the biology of essential tremor: from models to morphology. (24262197)
2014
10
Mitochondrial serine protease HTRA2 p.G399S in a kindred with essential tremor and Parkinson disease. (25422467)
2014
11
Functional Anatomy of Essential Tremor: Lessons from Neuroimaging. (23620075)
2013
12
Key issues in essential tremor genetics research: Where are we now and how can we move forward? (23450143)
2013
13
The microtubule associated protein tau H1 haplotype and risk of essential tremor. (24372973)
2013
14
Abnormal regional homogeneity in patients with essential tremor revealed by resting-state functional MRI. (23869236)
2013
15
Ocular flutter in essential tremor: clinical course and response to primidone. (24061767)
2013
16
Temporal discrimination in patients with dystonia and tremor and patients with essential tremor. (23243072)
2013
17
Is there a one-way street from essential tremor to Parkinson's disease? Possible biological ramifications. (24033795)
2013
18
Simultaneous thalamic and posterior subthalamic electrode insertion with single deep brain stimulation electrode for essential tremor. (22985104)
2013
19
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. (24096713)
2013
20
Neuroanatomical heterogeneity of essential tremor according to propranolol response. (24358327)
2013
21
Thalamic physiology of intentional essential tremor is more like cerebellar tremor than postural essential tremor. (23856324)
2013
22
Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. (22771283)
2012
23
Thalamic and subthalamic deep brain stimulation for essential tremor: where is the optimal target? (22426044)
2012
24
White matter hyperintensity burden on magnetic resonance imaging in essential tremor. (23439769)
2012
25
Blink reflex recovery cycle in patients with essential tremor associated with resting tremor. (22993289)
2012
26
Psychiatric disorders in patients with essential tremor. (22658234)
2012
27
Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor. (22519432)
2012
28
Blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor: repeat observation in cases and controls in New York. (22757671)
2012
29
Analysis of Lingo1 variant in sporadic and familial essential tremor among Asians. (21158743)
2011
30
Factors associated with receptivity to deep brain stimulation surgery among essential tremor cases. (21561796)
2011
31
Estimating annual rate of decline: prospective, longitudinal data on arm tremor severity in two groups of essential tremor cases. (21436230)
2011
32
Essential tremor--a neurodegenerative disorder associated with cognitive defects? (21487422)
2011
33
Marked reduction of tremor in essential tremor after putaminal infarct. (20581413)
2010
34
Long-term results of thalamic deep brain stimulation for essential tremor. (19911883)
2010
35
Screening for two SNPs of LINGO1 gene in patients with essential tremor or sporadic Parkinson's disease in Chinese population. (20600614)
2010
36
"Hairy baskets" associated with degenerative Purkinje cell changes in essential tremor. (20142764)
2010
37
Genetics of Parkinson disease and essential tremor. (20489616)
2010
38
Successful implantation of a deep brain stimulator for essential tremor in a patient with a preexisting cochlear implant: surgical technique: technical case report. (20489530)
2010
39
Tandem gait performance in essential tremor: clinical correlates and association with midline tremors. (20629168)
2010
40
Relationship between blood harmane and harmine concentrations in familial essential tremor, sporadic essential tremor and controls. (20708029)
2010
41
Gait and balance in essential tremor: variable effects of bilateral thalamic stimulation. (19006189)
2009
42
Prevalence of essential tremor: a door-to-door survey in Sile, Istanbul, Turkey. (18474448)
2009
43
An update on essential tremor. (19515278)
2009
44
Mirror movements in patients with essential tremor. (19795466)
2009
45
Fertility in essential tremor. Data from population-based and clinical sources. (18784418)
2008
46
Glutathione-S-transferase P1 polymorphism and risk for essential tremor. (18215156)
2008
47
The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. (18543121)
2008
48
Factors involved in long-term efficacy of deep brain stimulation of the thalamus for essential tremor. (18826350)
2008
49
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. (17353387)
2007
50
Manic-depressive illness associated with Klinefelter's syndrome and essential tremors. (655296)
1978

Variations for Essential Tremor

About this section

Expression for genes affiliated with Essential Tremor

About this section
Search GEO for disease gene expression data for Essential Tremor.

Pathways for genes affiliated with Essential Tremor

About this section

Pathways related to Essential Tremor according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.7PARK2, SLC6A3, SNCA
29.0HTRA2, LRRK2, PARK2, SLC6A3, SNCA

GO Terms for genes affiliated with Essential Tremor

About this section

Cellular components related to Essential Tremor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axonGO:00304249.7FMR1, LRRK2, SNCA

Biological processes related to Essential Tremor according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1dopamine metabolic processGO:004241710.5DRD3, SNCA
2regulation of neuron deathGO:190121410.5LRRK2, SNCA
3regulation of dopamine secretionGO:001405910.4DRD3, PARK2
4cellular response to dopamineGO:190335110.4LRRK2, PARK2
5dopamine uptake involved in synaptic transmissionGO:005158310.4PARK2, SNCA
6regulation of canonical Wnt signaling pathwayGO:006082810.4LRRK2, PARK2
7protein localization to mitochondrionGO:007058510.4LRRK2, PARK2
8regulation of neurotransmitter secretionGO:004692810.3PARK2, SNCA
9regulation of mitophagyGO:190314610.1HTRA2, PARK2
10adult locomotory behaviorGO:000834410.0HTRA2, SNCA
11positive regulation of proteasomal protein catabolic processGO:190180010.0FMR1, PARK2
12regulation of dopamine metabolic processGO:00420539.9PARK2, SLC6A3
13mitochondrion organizationGO:00070059.8HTRA2, LRRK2, PARK2
14response to cocaineGO:00422209.8HNMT, SNCA
15positive regulation of protein targeting to mitochondrionGO:19039559.8HNMT, HTRA2
16cellular protein catabolic processGO:00442579.7HTRA2, PARK2
17response to drugGO:00424939.5DRD3, SLC1A2, SLC6A3, SNCA
18synaptic transmission, dopaminergicGO:00019639.4DRD3, PARK2, SNCA

Molecular functions related to Essential Tremor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dopamine bindingGO:003524010.0DRD3, SLC6A3

Sources for Essential Tremor

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet